Background: To investigate the association between late preterm antenatal corticosteroid treatment and outcome in late preterm neonates born to mothers with gestational diabetes mellitus, Methods: All patients with gestational diabetes mellitus who had a late preterm delivery at Etlik Lady Zübeyde Hospital between 2017 and 2021 were included. Women who met the inclusion criteria and were not given antenatal corticosteroid treatment during current pregnancy before 34 0/7 weeks of gestation were divided into two groups according to whether or not they received late preterm antenatal corticosteroid treatment. The two groups were compared in terms of adverse neonatal complications. The main outcomes were composite respiratory outcome and composite neonatal outcome. Logistic regression analysis was used to determine additional potential predictors of neonatal outcome. Results: This retrospective cohort study included a total of 400 participants with gestational diabetes mellitus who had a late preterm delivery within the study period. Of these women, 196 (49%) received late preterm antenatal corticosteroid treatment. Main outcomes showed no difference. Decreasing gestational age at birth was identified as an independent risk factor predicting both composite respiratory outcome and composite neonatal outcome in multivariate logistic regression analysis. Conclusions: Antenatal corticosteroid treatment at or after 34 0/7 weeks of gestation in women with gestational diabetes mellitus who had a late preterm delivery was not associated with improvement in adverse neonatal outcomes. Decreasing gestational age at birth was the only independent risk factor predicting composite neonatal and composite respiratory outcomes.

Objective: To predict preeclampsia by the ratio of the HCG MoM value in the first and second trimester screening tests. Material and Methods: The HCG-MoM values of 136 pregnant women with preeclampsia and 222 normatensive pregnant women used for first- and second-trimester screening tests were proportioned , and the difference between the groups was examined. Results: The ratio of the free HCG MoM value in the first trimester to the intact HCG MoM value in the second trimester was significantly higher in the control group (1.06) than in the study group (0.99) (p=0.02). Conclusion: Rating the MoM values of β-HCG, a biochemical marker used in screening tests for chromosomal anomaly, may predict preeclampsia in the later weeks of pregnancy.

Exploring the Predictive Potential of Systemic Immune Inflammation Index and Hematologic Markers in Preterm Labor Risk Assessment - Gazi Medical Journal